Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with CD38 Expressing Relapsed/Refractory Acute Myeloid Leukemia

Guru Subramanian Guru Murthy, Jessica T. Leonard, Talha Badar, Cecilia Y. Arana Yi, Adam S Duvall, Bijal D. Shah, Arielle Baim, Tyce Kearl, Alexandra M. Harrington, Aniko Szabo, Ehab L. Atallah

Blood (2023) 142 (Supplement 1): 1541.

https://doi.org/10.1182/blood-2023-187721

Published: 2023

Journal Articles

Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies

Blood (2023) 142 (Supplement 1): 3192.

https://doi.org/10.1182/blood-2023-174790

Published: 2023

Journal Articles

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

Guru Subramanian Guru Murthy, Bijal D. Shah, Adam S Duvall, Jessica T. Leonard, Talha Badar, Cecilia Y. Arana Yi, Tyce Kearl, Arielle Baim, Alexandra M. Harrington, Aniko Szabo, Ehab L. Atallah

Blood (2023) 142 (Supplement 1): 4242.

https://doi.org/10.1182/blood-2023-187468

Published: 2023

Journal Articles

Comparable Survival of Treatment Naïve TP53 Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to Hypomethylating Agent Plus Venetoclax Based Therapy

Talha Badar, Ehab L. Atallah, Rory M. Shallis, Anand Ashwin Patel, Guilherme Sacchi De Camargo Correia, Aaron D. Goldberg, Antoine Saliba, Jan Philipp Bewersdorf, Adam S Duvall, Danielle Bradshaw, Yasmin Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Vamsi K. Kota, Mark R. Litzow

Blood (2023) 142 (Supplement 1): 592.

https://doi.org/10.1182/blood-2023-184626

Published: 2023

Journal Articles

Predictors of Long-Term Outcome in TP53 -Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar, Ehab L. Atallah, Rory Michael Shallis, Antoine N. Saliba, Maximilian F. Stahl, Jan Philipp Bewersdorf, Justin Grenet, Anand Ashwin Patel, Yasmin Abaza, Guru Subramanian Guru Murthy, Adam S Duvall, Madelyn Burkart, Neil Palmisiano, Michal Jakub Kubiak, Vamsi K. Kota, Shira Dinner, Aaron D Goldberg, Mark R. Litzow

Blood (2022) 140 (Supplement 1): 1435–1437.

https://doi.org/10.1182/blood-2022-167731

Published: 2022

Journal Articles

Outcomes of Patients Treated with Low-Intensity Re-Induction Therapy for Persistent Disease after a Single Intensive Induction Cycle for Newly Diagnosed Acute Myeloid Leukemia (AML)

Sameem Abedin, Skyler Taylor, Guru Subramanian Guru Murthy, Lyndsey Runaas, Laura C. Michaelis, Karen-Sue Carlson, Ehab L. Atallah

Blood (2022) 140 (Supplement 1): 11020–11021.

https://doi.org/10.1182/blood-2022-160416

Published: 2022

Journal Articles

Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features

Sameem Abedin, Guru Subramanian Guru Murthy, Aniko Szabo, Mehdi Hamadani, Laura C. Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Katelyn Gauger, Avinash G Desai, Mary M Chen, Alexandra M. Harrington, Ehab L. Atallah

Blood (2022) 140 (Supplement 1): 157–158.

https://doi.org/10.1182/blood-2022-157827

Published: 2022

Journal Articles

Clinical Outcomes of Patients with TP53 -Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar, Ehab L. Atallah, Antoine N. Saliba, Rory Michael Shallis, Maximilian F. Stahl, Jan Philipp Bewersdorf, Guillerhme Sacchi De Camargo Correia, Anand Ashwin Patel, Yasmin Abaza, Guru Subramanian Guru Murthy, Adam S Duvall, Madelyn Burkart, Neil Palmisiano, Danielle Bradshaw, Vamsi K. Kota, Shira Dinner, Aaron D Goldberg, Mark R. Litzow

Blood (2022) 140 (Supplement 1): 6058–6060.

https://doi.org/10.1182/blood-2022-163795

Published: 2022

Journal Articles

Outcomes of Patients with Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Current Era of Myeloid Therapies

Anand Ashwin Patel, James J. Yoon, Hannah Johnston, Evan C. Chen, Madelyn Burkart, Timothy Seijung Oh, Sunil G. Iyer, Ellen Madarang, Iyana Gross, Terrence Bradley, Yasmin Abaza, Jacqueline S. Garcia, Rory Michael Shallis, Guru Subramanian Guru Murthy, Vikas Gupta, Kristen M. Pettit, John Cursio, Olatoyosi Odenike

Blood (2022) 140 (Supplement 1): 6860–6862.

https://doi.org/10.1182/blood-2022-157603

Published: 2022

Journal Articles

Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adults with Acute Leukemia

Blood (2022) 140 (Supplement 1): 5083–5085.

https://doi.org/10.1182/blood-2022-159809

Published: 2022

Journal Articles

Assessment of Comorbidities and Their Association with Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL)Using Various Comorbidity-Based Scoring Systems

Ravi Kishore Narra, Ehab L. Atallah, Laura C. Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Aniko Szabo, Guru Subramanian Guru Murthy

Blood (2022) 140 (Supplement 1): 6035–6036.

https://doi.org/10.1182/blood-2022-165392

Published: 2022

Journal Articles

Major ABO Incompatibility Significantly Influences the Survival and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Leukemia - CIBMTR Analysis

Guru Subramanian Guru Murthy, Brent R. Logan, Stephanie Bo-Subait, Amer Beitingjaneh, Steven Devine, Nosha Farhadfar, Lohith Gowda, Shahrukh Hashmi, Hillard Lazarus, Sunita Nathan, Akshay Sharma, Jean A. Yared, Heather E. Stefanski, Michael A. Pulsipher, Jack W. Hsu, Galen E. Switzer, Sandhya R. Panch, Bronwen E. Shaw

Blood (2021) 138 (Supplement 1): 907.

https://doi.org/10.1182/blood-2021-150635

Published: 2021

Journal Articles

Superior Outcomes with Fludarabine-Busulfan (Flu/Bu) Based Conditioning for Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis - a Comparative Analysis By CIBMTR

Guru Subramanian Guru Murthy, Soyoung Kim, Noel Estrada-Merly, Ronald M. Sobecks, Betul Oran, Ryotaro Nakamura, Bart L. Scott, Wael Saber

Blood (2021) 138 (Supplement 1): 912.

https://doi.org/10.1182/blood-2021-147959

Published: 2021

Journal Articles

A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma

Blood (2021) 138 (Supplement 1): 4401.

https://doi.org/10.1182/blood-2021-149329

Published: 2021

Journal Articles

Lintuzumab-Ac225 in Combination with CLAG-M Yields High MRD (-) Responses in R/R AML with Adverse Features: Interim Results of a Phase I Study

Sameem Abedin, Guru Subramanian Guru Murthy, Mehdi Hamadani, Laura C. Michaelis, Lyndsey Runaas, Karen Carlson, Ehab L. Atallah

Blood (2021) 138 (Supplement 1): 3414.

https://doi.org/10.1182/blood-2021-148746

Published: 2021

Journal Articles

A First-in-Human Phase 1 Study of Oral LOXO-338, a Selective BCL2 Inhibitor, in Patients with Advanced Hematologic Malignancies (Trial in Progress)

Alvaro J. Alencar, Lindsey E. Roeker, Marc Hoffmann, Guru Subramanian Guru Murthy, Vishalkumar Patel, Nora C. Ku, James M. Pauff, Toby A. Eyre, Wojciech Jurczak, Steven Le Gouill

Blood (2021) 138 (Supplement 1): 2424.

https://doi.org/10.1182/blood-2021-145380

Published: 2021

Journal Articles

A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML)

Guru Subramanian Guru Murthy, Scott H. Kaufmann, Aniko Szabo, Alexandra M. Harrington, Laura C. Michaelis, Sameem Abedin, Karen Carlson, Lyndsey Runaas, Walter L. Longo, Alexander Hinman, Sonia Maldonado-Schmidt, Althea Thomas, Arielle Baim, Mark R. Litzow, Ehab L. Atallah

Blood (2021) 138 (Supplement 1): 2347.

https://doi.org/10.1182/blood-2021-149351

Published: 2021

Journal Articles

Younger HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Myelodysplastic Syndromes (MDS) Is Associated with Superior Disease-Free Survival Compared to Older HLA-Identical Sibling Donors: CIBMTR Analysis

Guru Subramanian Guru Murthy, MD, Soyoung Kim, Zhen-Huan Hu, MPH, Noel Estrada-Merly, MS, Ryotaro Nakamura, MD, Betul Oran, MDMS, Bart L. Scott, MD, Ronald Sobecks, MD, Wael Saber, MD MS

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-140647

Published: 2020

Journal Articles

Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study

Sameem Abedin, MD, Guru Subramanian Guru Murthy, MBBS, Lyndsey Runaas, MD, Laura C. Michaelis, MD, Ehab L. Atallah, MD, Mehdi Hamadani, MD, Alexandra M. Harrington, MDMT(ASCP), Karen Carlson, MD

Blood (2019) 134 (Supplement_1): 2605.

https://doi.org/10.1182/blood-2019-122487

Published: 2019

Journal Articles

Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Talha Badar, MD, Guru Subramanian Guru Murthy, MD, Lyndsey Runaas, MD, Karen-Sue B. Carlson, MD PhD, Laura C. Michaelis, MD, Alexandra M. Harrington, MDMT(ASCP), Ehab L. Atallah, MD, Sameem Abedin, MD

Blood (2019) 134 (Supplement_1): 5068.

https://doi.org/10.1182/blood-2019-123237

Published: 2019

NARROW

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with CD38 Expressing Relapsed/Refractory Acute Myeloid Leukemia

Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

Comparable Survival of Treatment Naïve TP53 Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to Hypomethylating Agent Plus Venetoclax Based Therapy

Predictors of Long-Term Outcome in TP53 -Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Outcomes of Patients Treated with Low-Intensity Re-Induction Therapy for Persistent Disease after a Single Intensive Induction Cycle for Newly Diagnosed Acute Myeloid Leukemia (AML)

Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features

Clinical Outcomes of Patients with TP53 -Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Outcomes of Patients with Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Current Era of Myeloid Therapies

Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adults with Acute Leukemia

Assessment of Comorbidities and Their Association with Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL)Using Various Comorbidity-Based Scoring Systems

Major ABO Incompatibility Significantly Influences the Survival and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Leukemia - CIBMTR Analysis

Superior Outcomes with Fludarabine-Busulfan (Flu/Bu) Based Conditioning for Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis - a Comparative Analysis By CIBMTR

A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma

Lintuzumab-Ac225 in Combination with CLAG-M Yields High MRD (-) Responses in R/R AML with Adverse Features: Interim Results of a Phase I Study

A First-in-Human Phase 1 Study of Oral LOXO-338, a Selective BCL2 Inhibitor, in Patients with Advanced Hematologic Malignancies (Trial in Progress)

A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML)

Younger HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Myelodysplastic Syndromes (MDS) Is Associated with Superior Disease-Free Survival Compared to Older HLA-Identical Sibling Donors: CIBMTR Analysis

Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study

Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only